Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net Sales	$ 7,836.2	$ 7,024.5	$ 7,982.2
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of products sold, excluding intangible asset amortization	$ 2,341.0	$ 2,128.3	$ 2,252.6
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Intangible asset amortization	$ 615.7	$ 597.6	$ 584.3
Research and development	497.2	372.0	449.3
Selling, general and administrative	3,323.9	3,177.8	3,343.8
Goodwill and intangible asset impairment	16.3	645.0	70.1
Restructuring and other cost reduction initiatives	129.1	116.9	50.0
Quality remediation	53.1	50.9	82.4
Acquisition, integration, divestiture and related	79.8	23.8	12.2
Operating expenses	7,056.1	7,112.3	6,844.7
Operating Profit (Loss)	780.1	(87.8)	1,137.5
Other income (expense), net	11.8	25.4	(4.8)
Interest expense, net	(208.4)	(212.0)	(226.9)
Loss on early extinguishment of debt	(165.1)
Earnings (Loss) before income taxes	418.4	(274.4)	905.8
Provision (benefit) for income taxes	16.3	(137.0)	(225.7)
Net Earnings (Loss)	402.1	(137.4)	1,131.5
Less: Net earnings (loss) attributable to noncontrolling interest	0.5	1.5	(0.1)
Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.	$ 401.6	$ (138.9)	$ 1,131.6
Earnings (Loss) Per Common Share - Basic	$ 1.93	$ (0.67)	$ 5.52
Earnings (Loss) Per Common Share - Diluted	$ 1.91	$ (0.67)	$ 5.47
Weighted Average Common Shares Outstanding
Basic	208.6	207.0	205.1
Diluted	210.4	207.0	206.7